International Consensus Reframes Diverticular Disease From Incidental Finding to Symptom-Driven Disorder
Colonic diverticulosis remains the most common structural abnormality of the colon in developed countries, but the Fiesole Consensus draws a sharp line between the incidental anatomic finding and the clinical syndrome that follows in a subset of patients. Diverticulosis now refers strictly to diverticula without symptoms, while diverticular disease applies when symptoms or complications are present. That distinction matters in everyday practice because it separates patients who need reassurance from those who need targeted evaluation for pain, inflammation, bleeding, or recurrent attacks.
The updated guidance arrives at a time when prevalence is rising globally and the biologic story has become more complex. Only about 20% to 25% of people with diverticulosis develop symptoms, yet those symptoms sit on a broad spectrum that includes functional complaints, acute diverticulitis, and surgical disease. In that setting, management cannot be reduced to a single algorithm. The consensus instead organizes care around epidemiology and pathogenesis, clinical features, diagnosis, medical therapy, and surgery, using a structured Delphi process grounded in PICO questions and GRADE methodology.
Risk Factors Point to Inflammation, Lifestyle, and Medication Exposure
The consensus identifies several exposures that increase risk, and the list is clinically familiar for a reason. High dietary fiber intake appears protective, while smoking and obesity increase risk, consistent with the broader concept that colonic wall stress, altered motility, and low-grade inflammation all contribute to symptom generation and complications. Medication exposure also matters. Non-steroidal anti-inflammatory drugs, corticosteroids, opioids, and immunotherapy are linked to higher risk, which fits with the ways these agents can impair mucosal integrity, alter immune surveillance, or mask evolving symptoms until disease is more advanced.
These observations are not just epidemiologic background. They help explain why patients with a similar anatomic burden can follow very different courses. A colon with diverticula does not automatically become a disease state; the transition depends on host susceptibility, microbial ecology, immune signaling, and exposure to drugs or behaviors that push the bowel toward inflammation or impaired healing.
Imaging Strategy Separates Uncomplicated Disease From Complicated Diverticulitis
When acute diverticulitis is suspected, imaging is essential. Ultrasound may be appropriate in experienced hands, but CT remains the preferred test for complicated cases. The consensus places imaging at the center of diagnosis because clinical symptoms alone cannot reliably distinguish uncomplicated inflammation from abscess, perforation, obstruction, or other urgent complications. In routine bedside care, that means the threshold for cross-sectional imaging should stay low when the presentation is severe, atypical, or out of proportion to the abdominal exam.
One short sentence captures the practical consequence: symptoms alone are not enough.
This approach also reflects a broader diagnostic truth. Acute diverticulitis can mimic appendicitis, ischemic bowel, inflammatory bowel disease, gynecologic pathology, and malignancy. Ultrasound may reduce radiation exposure and can perform well in skilled hands, but CT provides the anatomic detail needed to identify complications and guide escalation. For clinicians, the message is not to replace judgment with imaging, but to use imaging to anchor judgment in a condition where the same abdominal pain can represent very different risk.
Medical Therapy Targets Symptoms, Not the Diverticula Themselves
Diverticulosis itself requires no treatment. Once symptoms emerge, therapy shifts toward symptom control and prevention of recurrence rather than eradication of the diverticula. In symptomatic uncomplicated diverticular disease, dietary fiber, selected probiotics, mesalazine, and rifaximin may help relieve symptoms. Each of those options points to a different biologic lever: fiber alters stool bulk and transit, probiotics may influence the microbiome, mesalazine can modulate mucosal inflammation, and rifaximin offers a non-absorbed antimicrobial approach that may alter intestinal bacterial activity without the systemic burden of broader antibiotic exposure.
The consensus does not present these therapies as interchangeable cures. Instead, it places them in a symptom-focused framework that reflects the heterogeneity of diverticular disease. Some patients experience chronic pain or bloating with little objective inflammation, while others have recurrent inflammatory episodes that sit closer to classic diverticulitis. The treatment response is therefore likely to vary with the dominant mechanism in each patient. A fiber-first strategy may be appropriate for one person, while another may derive more benefit from a regimen aimed at microbiota-related symptoms or mucosal inflammation.
Antibiotics Lose Their Routine Role in Acute Uncomplicated Diverticulitis
Routine antibiotic use is not recommended for acute uncomplicated diverticulitis. This is one of the clearest shifts in modern management, and it reflects growing confidence that many uncomplicated attacks resolve without broad antimicrobial treatment. The reasoning is biologically plausible: not every localized inflammatory episode in the colon requires systemic bacterial suppression, especially when the patient is stable and imaging confirms an uncomplicated course.
For bedside practice, the change has immediate consequences. Fewer antibiotics mean less exposure to drug adverse effects, less selection pressure for resistance, and less disruption of the gut microbiome. It also forces clinicians to define “uncomplicated” carefully rather than using the label loosely. Patients who are febrile, immunocompromised, systemically unwell, or found to have complications on imaging still require a different approach. The consensus therefore narrows antibiotic use to the patients most likely to benefit, instead of treating every flare as though it were the same disease.
Surgery Is Individualized Around Quality of Life Rather Than Episode Count
Elective surgery should be individualized, with quality of life taking precedence over the raw number of prior episodes. That represents a major shift away from rigid episode-based thresholds and toward shared decision-making shaped by symptom burden, recurrence pattern, patient values, and the cumulative effect of the disease on daily function. Two patients with the same number of attacks may have very different needs: one may recover fully between episodes, while another may live with persistent pain, dietary restriction, anxiety, or repeated work loss.
A single operation is not automatically the right answer, and repeated attacks are not automatically the wrong one. The balance depends on how much the disease is changing the patient’s life and whether the expected benefits of resection outweigh surgical risk. By explicitly prioritizing quality of life, the consensus aligns surgical decision-making with the lived experience of diverticular disease rather than a calendar of prior flares.
Research Priorities Center on Microbiome, Genetics, and Long-Term Outcomes
The consensus also identifies unanswered scientific questions that remain central to the field. Microbiome characterization, genetic risk profiling, and long-term outcomes of selective antimicrobial and surgical strategies all sit near the top of the research agenda. Those priorities are logical because diverticular disease appears to be a convergence syndrome rather than a single-pathway disorder. Anatomical predisposition, microbial shifts, host genetics, immune signaling, and medication exposure likely interact over time.
Future work will need to determine which phenotypes truly benefit from rifaximin, mesalazine, probiotics, or surgery, and which patients can be managed conservatively with reassurance and monitoring. Long-term data will also be needed to clarify whether selective non-antibiotic strategies alter recurrence patterns, complication rates, or quality of life in a durable way. For now, the Fiesole Consensus provides a clinically usable framework that standardizes care across different healthcare systems while acknowledging how much remains unresolved at the mechanistic level.